Cortisone Injection for Hip Labral Tears: Limited Therapeutic Value
Cortisone injections provide minimal therapeutic benefit for hip labral tears and should not be considered a primary treatment option. While they may offer short-term diagnostic value and brief pain relief lasting approximately 9-10 days, they do not address the underlying structural pathology and carry meaningful risks.
Evidence Against Therapeutic Use
The most direct evidence comes from a prospective study specifically examining cortisone injections in patients with femoroacetabular impingement (FAI) and labral tears 1. Only 37% of patients reported clinically significant pain reduction at 14 days post-injection, dropping to just 6% at 6 weeks, with an average pain relief duration of only 9.8 days 1. This represents poor therapeutic efficacy for a structural problem.
In adolescents with hip pain and labral tears, 52% required surgery after cortisone injection within an average of 12.8 months 2. Critically, patients with FAI morphology were 10 times more likely to need surgery compared to those without bony abnormalities 2. This suggests injections merely delay definitive treatment in the presence of structural pathology.
Diagnostic vs. Therapeutic Role
The ACR Appropriateness Criteria (2017) rates image-guided anesthetic-corticosteroid injection as only "may be appropriate" (rating 5 out of 9) when labral tear is suspected 3. This rating indicates the procedure is primarily diagnostic rather than therapeutic - confirming intra-articular pain source rather than treating the labral pathology itself.
Risks Outweigh Benefits
Recent evidence on hip osteoarthritis reveals concerning safety signals that likely apply to labral tear patients:
- Rapidly progressive osteoarthritis (RPOA) occurred in approximately 7% of patients receiving hip corticosteroid injections 4
- 45.7% of patients with mild-moderate hip pathology showed radiographic progression after injection 5
- 87.6% ultimately required total hip arthroplasty at an average of 206 days post-injection 5
The FDA label for cortisone warns of multiple systemic effects including bone loss, cartilage damage, and adrenal suppression 6, though these are dose and duration-dependent.
Clinical Algorithm
For patients with confirmed hip labral tears:
If FAI morphology present (cam/pincer): Cortisone injection has limited value; proceed directly to surgical consultation as 90% will require surgery 2
If no bony abnormality: Consider single diagnostic injection - 90% may improve without surgery 2, but monitor closely for progression
If injection performed: Use lowest effective dose (evidence suggests 40mg triamcinolone or methylprednisolone for hip) 7, with ultrasound or fluoroscopic guidance 7
Expect short-term relief only: Average 9.8 days 1, not sustained beyond 3 months 4
Key Pitfalls to Avoid
- Do not use repeated injections - no evidence supports serial injections for labral tears, and risk of cartilage damage increases
- Do not delay definitive treatment in patients with structural FAI - injection will not prevent eventual surgery
- Do not inject within 3 months of planned surgery - infection risk increases from 0.5% to 1.0% 8
- Monitor diabetic patients closely - blood glucose elevation occurs days 1-3 post-injection 8
Bottom Line
Cortisone injections for hip labral tears function primarily as a diagnostic tool to confirm intra-articular pain, not as definitive treatment. The brief symptomatic relief (averaging 9-10 days) does not justify routine therapeutic use, particularly given emerging safety concerns about cartilage progression and the high likelihood of eventual surgical intervention in patients with underlying FAI morphology 1, 2, 5.